Merus N.V. (NASDAQ:MRUS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company’s bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. “

A number of other research analysts have also weighed in on the company. Royal Bank Of Canada initiated coverage on Merus N.V. in a report on Thursday, September 14th. They set an “outperform” rating and a $28.00 target price for the company. ValuEngine lowered Merus N.V. from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Merus N.V. in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $30.25.

Shares of Merus N.V. (MRUS) opened at $15.67 on Tuesday. Merus N.V. has a twelve month low of $13.13 and a twelve month high of $33.63.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at

A hedge fund recently bought a new stake in Merus N.V. stock. Renaissance Technologies LLC bought a new position in Merus N.V. (NASDAQ:MRUS) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 22,500 shares of the biotechnology company’s stock, valued at approximately $549,000. Renaissance Technologies LLC owned about 0.14% of Merus N.V. at the end of the most recent reporting period. 31.52% of the stock is owned by institutional investors.

Merus N.V. Company Profile

Receive News & Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.